You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. ANYTIME, ANYPLACE LEARNING FOR CRITICAL CARE

    SBC: ACADEMIC EDGE, INC.            Topic: N/A

    completion, the entire course will provide a professional certificate with continuing nursing education contact hours or can be transferred as academic credit in an undergraduate-nursing program. The model for the OCPP to be developed in this project has three components: didactic core content, clinical practicum, and a Virtual Center of Best Practices. The core ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  2. A device containing immobilized chelator to remove aluminum from TPN solutions

    SBC: ALKYMOS, INC            Topic: N/A

    DESCRIPTION (provided by applicant): A high percentage of the ~ 470,000 children born prematurely each year in the US require intravenous feeding after birth because they do not tolerate oral feeding. This is accomplished with a total parenteral nutrition (TPN) solution, which is prepared from component solutions: small and large volume parenterals (SVPs and LVPs). Aluminum (Al) is a common conta ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  3. Transdermal Cannabidiol Delivery for Alcohol-Induced Neurodegeneration

    SBC: ALLTRANZ, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Treatment of alcohol use disorders (AUDs), commonly referred to as alcoholism, has been hampered by alcohol's promiscuous pharmacological effects and the complex etiology of addiction. People drink in excess for a variety of reasons, and an approach that targets more of these reasons will have greater commercial success than an approach that only targets a sole ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  4. A NOVEL ADJUVANT FOR TUMQR VACCINATION

    SBC: APOIMMUNE, INC            Topic: N/A

    DESCRIPTION (provided by applicant): Cancer continues to be a leading cause of death in the U.S. and in many other countries. Cancers develop and spread within the body when tumor cells are not detected or destroyed by the immune system. Although certain new therapies hold promise, current cancer treatments, including chemotherapy and radiation therapy, tend to kill cells non-selectively and can ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  5. ApoVax-SVN as a Novel Vaccine for Cancer Immunotherapy

    SBC: APOIMMUNE, INC            Topic: N/A

    DESCRIPTION (provided by applicant): The main objective of this proposal is to develop a novel cancer vaccine, ApoVax-SVN(tm) based on the use of a proprietary costimulatory chimeric ligand, 4-1BBL, designed to specifically deliver survivin, a tumor associated antigen (TAA) to professional antigen-presenting cells (APCs) and activate them for the generation of an effective anti-tumor immune respon ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  6. PPMP as a Ceramide Catabolism Inhibitor for Chemotherapy

    SBC: AVANTI POLAR LIPIDS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Our goal is to develop 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP) as a clinical inhibitor of ceremide catabolism, in order to enhance the anti-cancer activity of the cytotoxic retinoid, fenretinide (4-HPR). We have reported that 4-HPR increased ceramide in numerous pediatric and adult solid cancer and leukemia cell lines in vitro. We have also ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  7. Optimal Hydrophobicity of Lipoid Gene Delivery Agents

    SBC: AVANTI POLAR LIPIDS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Cationic lipid-like compounds are commonly used in vitro and in vivo to deliver DNA to cells for the purposes of expressing exogenous genes. A number of clinical trials have indicated the promise of these agents for gene therapy, however lipid-based delivery remains less effective than the alternative viral vectors. Nevertheless, vast improvements have been mad ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  8. Novel Reagents to Bypass Limitations of Existing Coagulation Assays

    SBC: AVANTI POLAR LIPIDS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): We propose to identify an optimal short carbon chain lipid species to be used as a surrogate for membranes in a novel and improved blood coagulation factor assays that will improve rapid diagnosis of coagulation disorders. Blood coagulation protects the integrity of damaged blood vessels and is localized specifically to cells at a site of injury by exposure of ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  9. Exosomal microRNA profiles as diagnostic biomarkers of ovarian cancer

    SBC: TEKSHIFA, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Detection of ovarian cancer at Stage I results in 5-year survivals of greater than 90%; however, only 23% of ovarian cancers are diagnosed early, with 67% being diagnosed with metastatic disease. Thus, new markers are being sought to accurate identify patients with ovarian cancer, particularly in early stage. Emerging evidence suggests the potential involvement ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  10. Prototype of Adjustable Systemic-Pulmonary Artery Shunt

    SBC: Cardiojustable, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This proposal is to complete the feasibility prototype of an adjustable systemic-pulmonary artery (SPA) shunt. Children with single ventricle physiology (SVP) and reduced pulmonary blood flow (PBF) are palliated with an SPA shunt until approximately 6 months of age. Current shunts are made from simple (unadjustable) polytetrafluoroethylene (PTFE) vascular gr ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government